Drug interactions
Tafamidis meglumine + Topotecan
Severity: Minor
Tafamidis meglumine and Topotecan: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tafamidis meglumine inhibits BCRP in vitro and may increase exposure to BCRP substrates such as topotecan. The effect on topotecan has not been well characterized, but higher levels could increase myelosuppression.
What this interaction means in plain words
Tafamidis meglumine and Topotecan have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Tafamidis inhibits BCRP, which can reduce topotecan efflux.
What to do
Monitor blood counts during topotecan therapy and lower the topotecan dose if toxicity occurs.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Tafamidis meglumine and Topotecan, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Topotecan
- Adenovirus types 4 and 7 live + Topotecan Contraindicated
- Amiodarone + Topotecan Major
- Cisplatin + Topotecan Major
- Cobicistat + Topotecan Major
- Cyclosporine + Topotecan Major
- Cyclosporin + Topotecan Major
Frequently asked questions
Can I take Tafamidis meglumine with Topotecan?
MediHelp rates the interaction as minor. Tafamidis meglumine and Topotecan have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Tafamidis meglumine inhibits BCRP in vitro and may increase exposure to BCRP substrates such as topotecan. The effect on topotecan has not been well characterized, but higher levels could increase myelosuppression.
How serious is the interaction between Tafamidis meglumine and Topotecan?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts during topotecan therapy and lower the topotecan dose if toxicity occurs.
What other medicines interact with Topotecan?
MediHelp also lists interactions of Topotecan with, for example, Adenovirus types 4 and 7 live, Amiodarone, Cisplatin. The full list is on the Topotecan page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
